A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.
Chemical ID:
MESH:D009538
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Melatonin inhibits the reaction [Nicotine results in decreased expression of MAPK3 protein]; Melatonin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK3 protein; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased phosphorylation of MAPK3 protein; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of FOS protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of JUN protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] which results in decreased susceptibility to Nicotine; Acetylcysteine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine results in decreased activity of MAPK3 protein]; Curcumin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Nicotine inhibits the reaction [Cisplatin results in increased activity of MAPK3 protein]; Nicotine inhibits the reaction [Fluorouracil results in increased phosphorylation of MAPK3 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; Nicotine results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein; Propranolol inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]